You are here
Diplomat Expands AdhereTech Relationship as Program Shows Increased Adherence and Persistence
FLINT, Mich., April 10, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is expanding its relationship with AdhereTech to include more manufacturers' products. AdhereTech's smart pill bottles help to support patient adherence and persistence to prescribed medication regimens. The bottles also collect adherence data that should help Diplomat improve patient care.
AdhereTech's smart pill bottles have sensors to record medication use in real time. Patients receive medication reminders after missing a dose. The device can also trigger a call from the patient's care team for additional support.
Diplomat and AdhereTech collaborated on a rollout of the program. Patients using selected medications could choose to use AdhereTech smart pill bottles. Diplomat and AdhereTech jointly analyzed these patients' results, comparing them to the patients' adherence metrics before utilizing the smart-bottle program.
Over a year, the average patient using AdhereTech bottles experienced:
- More than one additional medication fill
- 12 percent higher patient retention rate
- 19 fewer gap days (time without medication between fills)
Following this successful program launch, Diplomat and AdhereTech are expanding the smart-bottle program to products from additional pharmaceutical manufacturers — giving thousands more patients access to this technology that should help improve their adherence to therapy.
Gary Rice, executive vice president at Diplomat, said expanding the AdhereTech program shows Diplomat's commitment to helping patients in innovative ways.
"We're proud to partner with AdhereTech to provide our patients with one more tool to manage chronic and complex conditions," Rice said. "Diplomat's philosophy is 'Take good care of patients and the rest falls into place.' Accordingly, this program improves patients' treatment experience and enhances patient care."
To learn more about Diplomat, visit diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and may include Diplomat's expectations regarding increased adherence rates, additional medication fills, higher fill-to-fill retention rates and shorter periods without medication between fills for patients (and any implied financial impact). The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: the efficacy of AdhereTech's technology and associated increase in adherence rates, as well as any financial impact of such increased adherence rates; maintaining existing patients; supply disruption of any of the specialty drugs we dispense; our ability to expand the number of specialty drugs we dispense and related services; bad publicity about, or market withdrawal of, specialty drugs we dispense; our ability to drive volume through a refreshed marketing strategy in traditional specialty pharmacy; and the additional factors set forth in "Risk Factors" in Diplomat's most recent Annual Report on Form 10-K, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments, or otherwise.
Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy and infusion services. Diplomat helps people with complex and chronic health conditions in all 50 states, partnering with payers, providers, hospitals, manufacturers, and more. Rooted in this patient care expertise, Diplomat also serves payers through CastiaRx, a leading specialty benefit manager, and offers tailored solutions for healthcare innovators through EnvoyHealth. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues — always focused on improving patient care. For more information, visit diplomat.is.
AdhereTech provides pharma-sponsored support programs to patients on specialty medications, all powered by its patented smart pill bottles. Customers include many of the largest pharma companies and specialty medications, as well as most of the top specialty pharmacies in the US. Patients receive a smart pill bottle from the specialty pharmacy, with their fill of a specialty medication. The bottles work right out of the box, with zero setup. Patients simply use it just like a normal bottle, and automatically get all of the benefits of the program, including helpful reminders for missed doses. The system is intelligent and will only send a reminder when a dose is missed. Additionally, the program also provides personalized support for refills & health issues. If a patient needs additional support, AdhereTech's system notifies their pharmacy or healthcare provider. The pharmacy or healthcare provider then knows about important issues earlier, so they can contact the patient to provide support, sooner than ever before possible. Learn more at www.adheretech.com.
Terri Anne Powers, Vice President of Investor Relations
312.889.5244 | email@example.com
Kali Lucas, Partner Marketing Supervisor
810.768.9580 | firstname.lastname@example.org
View original content to download multimedia:http://www.prnewswire.com/news-releases/diplomat-expands-adheretech-relationship-as-program-shows-increased-adherence-and-persistence-300830165.html
SOURCE Diplomat Pharmacy, Inc.